47 related articles for article (PubMed ID: 26475207)
1. FLT3-ITD drives Ara-C resistance in leukemic cells via the induction of RUNX3.
Damdinsuren A; Matsushita H; Ito M; Tanaka M; Jin G; Tsukamoto H; Asai S; Ando K; Miyachi H
Leuk Res; 2015 Dec; 39(12):1405-13. PubMed ID: 26475207
[TBL] [Abstract][Full Text] [Related]
2. Complex molecular genetic abnormalities involving three or more genetic mutations are important prognostic factors for acute myeloid leukemia.
Wakita S; Yamaguchi H; Ueki T; Usuki K; Kurosawa S; Kobayashi Y; Kawata E; Tajika K; Gomi S; Koizumi M; Fujiwara Y; Yui S; Fukunaga K; Ryotokuji T; Hirakawa T; Arai K; Kitano T; Kosaka F; Tamai H; Nakayama K; Fukuda T; Inokuchi K
Leukemia; 2016 Mar; 30(3):545-54. PubMed ID: 26488113
[TBL] [Abstract][Full Text] [Related]
3. JMJD1C is required for the survival of acute myeloid leukemia by functioning as a coactivator for key transcription factors.
Chen M; Zhu N; Liu X; Laurent B; Tang Z; Eng R; Shi Y; Armstrong SA; Roeder RG
Genes Dev; 2015 Oct; 29(20):2123-39. PubMed ID: 26494788
[TBL] [Abstract][Full Text] [Related]
4. Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo.
Arreba-Tutusaus P; Mack TS; Bullinger L; Schnöder TM; Polanetzki A; Weinert S; Ballaschk A; Wang Z; Deshpande AJ; Armstrong SA; Döhner K; Fischer T; Heidel FH
Leukemia; 2016 May; 30(5):1220-1225. PubMed ID: 26487272
[No Abstract] [Full Text] [Related]
5. Targeting mitochondrial RNA polymerase in acute myeloid leukemia.
Bralha FN; Liyanage SU; Hurren R; Wang X; Son MH; Fung TA; Chingcuanco FB; Tung AY; Andreazza AC; Psarianos P; Schimmer AD; Salmena L; Laposa RR
Oncotarget; 2015 Nov; 6(35):37216-28. PubMed ID: 26484416
[TBL] [Abstract][Full Text] [Related]
6. CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.
Bertoli S; Boutzen H; David L; Larrue C; Vergez F; Fernandez-Vidal A; Yuan L; Hospital MA; Tamburini J; Demur C; Delabesse E; Saland E; Sarry JE; Galcera MO; Mansat-De Mas V; Didier C; Dozier C; Récher C; Manenti S
Oncotarget; 2015 Nov; 6(35):38061-78. PubMed ID: 26515730
[TBL] [Abstract][Full Text] [Related]
7. IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association.
Debarri H; Lebon D; Roumier C; Cheok M; Marceau-Renaut A; Nibourel O; Geffroy S; Helevaut N; Rousselot P; Gruson B; Gardin C; Chretien ML; Sebda S; Figeac M; Berthon C; Quesnel B; Boissel N; Castaigne S; Dombret H; Renneville A; Preudhomme C
Oncotarget; 2015 Dec; 6(39):42345-53. PubMed ID: 26486081
[TBL] [Abstract][Full Text] [Related]
8. Metformin synergistically sensitizes FLT3-ITD-positive acute myeloid leukemia to sorafenib by promoting mTOR-mediated apoptosis and autophagy.
Wang F; Liu Z; Zeng J; Zhu H; Li J; Cheng X; Jiang T; Zhang L; Zhang C; Chen T; Liu T; Jia Y
Leuk Res; 2015 Dec; 39(12):1421-7. PubMed ID: 26505133
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD.
Ho AD; Schetelig J; Bochtler T; Schaich M; Schäfer-Eckart K; Hänel M; Rösler W; Einsele H; Kaufmann M; Serve H; Berdel WE; Stelljes M; Mayer J; Reichle A; Baldus CD; Schmitz N; Kramer M; Röllig C; Bornhäuser M; Thiede C; Ehninger G;
Biol Blood Marrow Transplant; 2016 Mar; 22(3):462-9. PubMed ID: 26551637
[TBL] [Abstract][Full Text] [Related]
10. Expression of GADS enhances FLT3-induced mitogenic signaling.
Chougule RA; Cordero E; Moharram SA; Pietras K; Rönnstrand L; Kazi JU
Oncotarget; 2016 Mar; 7(12):14112-24. PubMed ID: 26895103
[TBL] [Abstract][Full Text] [Related]
11. The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells.
Chang E; Ganguly S; Rajkhowa T; Gocke CD; Levis M; Konig H
Leukemia; 2016 May; 30(5):1025-32. PubMed ID: 26686245
[TBL] [Abstract][Full Text] [Related]
12. SKLB-677, an FLT3 and Wnt/β-catenin signaling inhibitor, displays potent activity in models of FLT3-driven AML.
Ma S; Yang LL; Niu T; Cheng C; Zhong L; Zheng MW; Xiong Y; Li LL; Xiang R; Chen LJ; Zhou Q; Wei YQ; Yang SY
Sci Rep; 2015 Oct; 5():15646. PubMed ID: 26497577
[TBL] [Abstract][Full Text] [Related]
13. Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia.
Churpek JE; Pyrtel K; Kanchi KL; Shao J; Koboldt D; Miller CA; Shen D; Fulton R; O'Laughlin M; Fronick C; Pusic I; Uy GL; Braunstein EM; Levis M; Ross J; Elliott K; Heath S; Jiang A; Westervelt P; DiPersio JF; Link DC; Walter MJ; Welch J; Wilson R; Ley TJ; Godley LA; Graubert TA
Blood; 2015 Nov; 126(22):2484-90. PubMed ID: 26492932
[TBL] [Abstract][Full Text] [Related]
14.
Ito K; Otani S; Date Y
Cells; 2023 Apr; 12(8):. PubMed ID: 37190031
[TBL] [Abstract][Full Text] [Related]
15. Prognostication refinement in NPM1-mutated acute myeloid leukemia stratified by FLT3-ITD status with different induction doses of cytarabine.
Wang B; Hua X; Zhang J; Gu W; Li H
Cancer Med; 2023 Apr; 12(8):9420-9433. PubMed ID: 36808479
[TBL] [Abstract][Full Text] [Related]
16. Resistance Mechanism of Acute Myeloid Leukemia Cells Against Daunorubicin and Cytarabine: A Literature Review.
Arwanih EY; Louisa M; Rinaldi I; Wanandi SI
Cureus; 2022 Dec; 14(12):e33165. PubMed ID: 36726936
[TBL] [Abstract][Full Text] [Related]
17. Deciphering the Therapeutic Resistance in Acute Myeloid Leukemia.
Gurnari C; Pagliuca S; Visconte V
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33198085
[TBL] [Abstract][Full Text] [Related]
18. Elevated expression of RUNX3 co-expressing with EZH2 in esophageal cancer patients from India.
Rehman AU; Iqbal MA; Sattar RSA; Saikia S; Kashif M; Ali WM; Medhi S; Saluja SS; Husain SA
Cancer Cell Int; 2020; 20():445. PubMed ID: 32943993
[TBL] [Abstract][Full Text] [Related]
19. Brentuximab vedotin for refractory anaplastic lymphoma kinase-negative anaplastic large cell lymphoma in leukemic phase with
Yamashita Y; Hori Y; Kosako H; Oiwa T; Warigaya K; Mushino T; Murata S; Fujimoto M; Nishikawa A; Murata SI; Sonoki T; Tamura S
Hematol Rep; 2020 May; 12(1):8368. PubMed ID: 32499905
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic RUNX3: A Link between p53 Deficiency and MYC Dysregulation.
Date Y; Ito K
Mol Cells; 2020 Feb; 43(2):176-181. PubMed ID: 31991537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
